



31st international
symposium
on ALS/MND

31st international symposium on ALS/MND

Virtual

9 - 11 December 2020

Programme

Organised by the Motor Neurone Disease Association in co-operation
with the International Alliance of ALS/MND Associations



DAY 1 (Wednesday 9 December)

SESSION 1: OPENING SESSION

GMT	EST	JST	PRESENTATION	SPEAKER
1300 - 1305	0800 - 0805	2200 - 2205	Welcome to the 31st International Symposium on ALS/MND	
1305 - 1355	0805 - 0855	2205 - 2255	The Stephen Hawking Memorial Lecture: #C1: Targeting neuroinflammation across neurodegenerative diseases Discussion/Questions	L Hawking (UK) R Tanzi (USA)
1355 - 1405	0855 - 0905	2255 - 2305	International Alliance of ALS/MND Associations Forbes Norris and Humanitarian Awards	
1405 - 1420	0905 - 0920	2305 - 2320	IPG Award and winner's research presentation	

SESSION 2: PROTEIN DYSREGULATION AND PROTEOTOXICITY

GMT	EST	JST	PRESENTATION	SPEAKER
1430 - 1450	0930 - 0950	2330 - 2350	#C2: Prions, prionoids and neurodegeneration	A Aguzzi (Switzerland)
1450 - 1510	0950 - 1010	2350 - 0010	#C3: Protein dysregulation in ALS	D Bosco (USA)
1510 - 1530	1010 - 1030	0010 - 0030	#C4: Protein quality control of biomolecular condensates: Implications for ALS and frontotemporal degeneration	S Carra (Italy)
1530 - 1540	1030 - 1040	0030 - 0040	Discussion/Questions	

SESSION 3: CLINICAL TRIALS

GMT	EST	JST	PRESENTATION	SPEAKER
1550 - 1610	1050 - 1110	0050 - 0110	#C5: The REFALS phase 3 study of levosimendan in patients with ALS	M Cudkowicz (USA)
1610 - 1630	1110 - 1130	0110 - 0130	#C6: NurOwn ALS Phase 3 clinical trial update	R Kern (Israel) M Cudkowicz (USA)
1630 - 1650	1130 - 1150	0130 - 0150	#C7: Functional and long-term survival benefit of AMX0035 in ALS: Results of the CENTAUR and Open Label Extension trials	S Paganoni (USA)
1650 - 1700	1150 - 1200	0150 - 0200	Discussion/Questions	

LIVE POSTER SESSION A

GMT: 1710 - 1750 | EST: 1210 - 1250 | JST: 0210 - 0250

DAY 2 (Thursday 10 December)

GMT	EST	JST	PRESENTATION	SPEAKER
1300 - 1305	0800 - 0805	2200 - 2205	Welcome to Day 2	

SESSION 4: FROM RESEARCH TO CARE

GMT	EST	JST	PRESENTATION	SPEAKER
1305 - 1325	0805 - 0825	2205 - 2225	#C8: The power of ALS patient registries in the age of personalized medicine	O Hardiman (Ireland)
1325 - 1345	0825 - 0845	2225 - 2245	#C9: Improving patient-reported outcome measures in ALS/MND	C Young (UK)
1345 - 1405	0845 - 0905	2245 - 2305	#C10: Assessment of ALS disease progression from accelerometer and voice recordings using machine learning with application to the evaluation of real-world drug efficacy	F Vieira (USA)
1405 - 1415	0905 - 0915	2305 - 2315	Discussion/Questions	

SESSION 5: ALS/MND PATHOGENESIS

GMT	EST	JST	PRESENTATION	SPEAKER
1430 - 1450	0930 - 0950	2330 - 2350	#C11: Spatiotemporal dynamics of molecular pathology in ALS	H Phatnani (USA)
1450 - 1510	0950 - 1010	2350 - 0010	#C12: DNA methylation studies in ALS and age acceleration	E Rogaeva (Canada)
1510 - 1530	1010 - 1030	0010 - 0030	#C13: Defective RNA metabolism in ALS: TDP-43 loss of function and stress granule dynamics	C Vande Velde (Canada)
1530 - 1540	1030 - 1040	0030 - 0040	Discussion/Questions	

SESSION 6: THERAPEUTIC STRATEGIES

GMT	EST	JST	PRESENTATION	SPEAKER
1550 - 1610	1050 - 1110	0050 - 0110	#C14: ASOs for neuromuscular diseases: Yesterday, today and tomorrow	A Chio (Italy)
1610 - 1630	1110 - 1130	0110 - 0130	#C15: Modulating disease-modifying genes in ALS	A Gitler (USA)
1630 - 1650	1130 - 1150	0130 - 0150	#C16: MR-guided focused ultrasound: A new frontier in the delivery of biotherapeutics for ALS	L Zinman (Canada) A Abrahao (Canada)
1650 - 1700	1150 - 1200	0150 - 0200	Discussion/Questions	

LIVE POSTER SESSION B

GMT: 1710 - 1750 | EST: 1210 - 1250 | JST: 0210 - 0250

DAY 3 (Friday 11 December)

GMT	EST	JST	PRESENTATION	SPEAKER
1200 - 1205	0700 - 0705	2100 - 2105	Welcome to Day 3	

LIVE POSTER SESSION C

GMT: 1205 - 1250 | EST: 0705 - 0750 | JST: 2105 - 2150

SESSION 7: PERSPECTIVES – LESSONS FROM COVID-19

GMT	EST	JST	PRESENTATION	SPEAKER
1305 - 1335	0805 - 0835	2205 - 2235	#C17: Implications for clinical trials and drug development	A Genge (Canada)
			#C17: Impact on palliative care for ALS/MND	R Burman (UK)
			#C17: Impact on basic and translational science	C Bendotti (Italy)
			#C17: Impact on living with ALS/MND	B Virgo (UK)
1335 - 1405	0835 - 0905	2235 - 2305	Discussion/Questions	

SESSION 8: COGNITIVE CHANGE

GMT	EST	JST	PRESENTATION	SPEAKER
1420 - 1440	0920 - 0940	2320 - 2340	#C18: Are we there yet? Measuring nonmotor progression in ALS	M Strong (Canada)
1440 - 1500	0940 - 1000	2340 - 0000	#C19: Selective vulnerability in frontotemporal dementia and ALS	W Seeley (USA)
1500 - 1520	1000 - 1020	0000 - 0020	#C20: The role of the cerebellum in cognition: Implications for ALS	J Schmahmann (USA)
1520 - 1530	1020 - 1030	0020 - 0030	Discussion/Questions	

SESSION 9: CLOSING SESSION

GMT	EST	JST	PRESENTATION	SPEAKER
1550 - 1600	1050 - 1100	0050 - 0100	Invitation to Basel 2021	
1600 - 1615	1100 - 1115	0100 - 0115	Healey Center Award	
1615 - 1640	1115 - 1140	0115 - 0140	#C21: Open drug discovery: From genes to affordable medicines	A Edwards (Canada)
1640 - 1650	1140 - 1150	0140 - 0150	Discussion/Questions	
1650 - 1700	1150 - 1200	0150 - 0200	#C22: ALS Diagnostic Criteria - The Gold Standard	M Kiernan (Australia)
1700 - 1715	1200 - 1215	0200 - 0215	Final Thoughts	

With grateful thanks to the supporters of the
31st International Symposium on ALS/MND



Mitsubishi Tanabe Pharma

